Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Duodenal Ulcer
Interventions
DRUG

LXI-15028 50mg group

The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks

DRUG

Lansoprazole 30mg group

The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.

Trial Locations (1)

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

INDUSTRY

NCT05010954 - Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer | Biotech Hunter | Biotech Hunter